MET and non-small cell lung carcinoma: Other molecules for MET-altered NSCLC are under investigation in early phase clinical trials (Table 2) including: glumetinib and APL-101 (oral MET inhibitors); SAR125844, a MET inhibitor administered intravenously; glesatinib (MGCD265) with activity against MET; VEGFR1/2/3; RON; TIE-2; and elzovantinib (TPX-022), a potent MET/CSF1R/SRC inhibitor.